Drug intelligence / Profile preview

CalRexin therapeutic conjugates

Development stage: Preclinical
Lead developer: Apop Biosciences
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CalRexin therapeutic conjugates are antibody-drug conjugates being developed by Apop Biosciences. These conjugates utilize the company's proprietary CalRexin antibody technology that targets the calcitonin receptor, which appears on the surface of stressed cells undergoing processes like apoptosis and autophagy. The technology is being developed as a delivery vehicle for therapeutics in the form of antibody-toxin and antibody-drug conjugates specifically designed to treat refractory tumors.

Targets

CALCR (Calcitonin receptor)

Beyond the preview

Go deeper on CalRexin therapeutic conjugates.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CalRexin therapeutic conjugates.

Explore the full profile